Results 161 to 170 of about 20,576 (195)

Budget Impact of Faricimab in Neovascular Age-Related Macular Degeneration in the Netherlands: A Systematic Review and Meta-Analysis of Injection Count. [PDF]

Ophthalmol Ther
El Alili M, van de Laar CJ, de Greeff JPF, Vromans JGF, van Asten F, Bosmans JE.   +5 more
europepmc   +1 more source

Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group. [PDF]

Int J Retina Vitreous
Wu L, Rojas S, Rao X, Politis M, Roca JA, Nehemy M, Berrocal MH, Fromow-Guerra J, Barraza-Lino K, Lopez C, Maia M, Cardenas-Mirón A, Gabela G, Baldivieso-Hurtado O, Gabela C, Chinchilla L, Verdaguer JI, Zas M, Young M, García-Aguirre G, Ramirez-Estudillo JA, Abreu N, Flores M, Velez W, Baez Y, Arriola-Lopez A, Casella AM.   +26 more
europepmc   +1 more source

Comparative Real-World Efficacy of Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Study.

Ophthalmologica
Berco E, Kozlov Y, Ostrovsky M, Tuli R, Kin Man Lee T, Samocha K, Shcolnik E, Goldfeather Ben Zaken S, Shoham-Hazon N.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aflibercept

Reactions Weekly, 2022
  +9 more sources

Aflibercept

Reactions Weekly, 2017
  +7 more sources

Aflibercept

Reactions Weekly, 2019
  +8 more sources

Aflibercept

Reactions Weekly, 2020
  +5 more sources

Aflibercept

Reactions Weekly, 2018
  +6 more sources

Aflibercept

Reactions Weekly, 2023
  +4 more sources